Intel stock spikes after report of possible US government stake
Melissa Baird, the Chief Operating Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions, according to a recent SEC filing. On April 9, Baird sold a total of 33,337 shares of Class A Common Stock, amounting to $910,687. The shares were sold at prices ranging from $25.8234 to $29.2258 per share. With the stock currently trading at $26.83 and the company showing strong revenue growth of 69%, InvestingPro analysis suggests the stock is fairly valued at current levels.
In addition to these sales, Baird exercised stock options to acquire 33,337 shares at a price of $1.75 each, totaling $58,339. Following these transactions, Baird holds 805,083 shares directly in the company, representing a significant stake in this $5.92 billion market cap healthcare technology firm. These transactions were conducted under a Rule 10b5-1 trading plan, which was adopted on November 26, 2024.
In other recent news, Hims & Hers Health has announced the expansion of its pharmaceutical offerings to include Eli Lilly (NYSE:LLY)'s diabetes and weight-loss drug, Zepbound, as well as generic versions of liraglutide. This development has attracted attention from various analyst firms. Truist Securities maintained a Hold rating with a $39.00 price target, noting that while the inclusion of these products could attract more users, the branded tirzepatide is not expected to significantly boost revenue. Leerink Partners also maintained a Market Perform rating with a $40.00 target, expressing caution over the high cost of Zepbound, which could impact consumer demand.
BofA Securities reiterated an Underperform rating with a $22.00 target, highlighting that the margins on branded drugs like Zepbound are lower than Hims & Hers' typical gross margins. They suggested the decision to offer Zepbound might be more about providing consumer choice rather than driving substantial sales. Despite this, the market responded positively to the news, reflecting investor optimism about the company's strategic direction in the telehealth space. Hims & Hers aims to leverage this expansion to better serve customer needs, aligning with broader industry trends of increasing online drug accessibility. The company's move mirrors actions by peers such as Teladoc (NYSE:TDOC) and LifeMD, emphasizing the growing role of telehealth platforms in the pharmaceutical distribution chain.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.